EGFR ligands dictate tumour suppression

Article Multidisciplinary Sciences

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Chun Hu et al.

Summary: The epidermal growth factor receptor (EGFR) frequently mutates in human cancer, and is an important therapeutic target. However, EGFR inhibitors have limited effectiveness in glioblastoma multiforme (GBM) due to exclusive mutations in the extracellular region. This study reveals that GBM mutations impair EGFR's ability to distinguish between activating ligands, which may have implications for therapeutic targeting.

NATURE (2022)

Add to Collection

Article Cell Biology

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

Gao Guo et al.

Summary: In this study, the authors discovered a new tumor-suppressive function of EGFR in EGFR-amplified glioblastomas. They found that the level of EGFR ligands can shift the role of EGFR from an oncogene to a tumor suppressor, influencing the prognosis of the disease. Increasing the level of EGFR ligands can activate the tumor-suppressive function of EGFR, resulting in inhibited tumor growth and invasion.

NATURE CELL BIOLOGY (2022)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Oncology